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Abstract
Background: There are few data regarding clinical care and outcomes of Indigenous Australians living with HIV
and it is unknown if these differ from non-Indigenous HIV-positive Australians.
Methods: AHOD commenced enrolment in 1999 and is a prospective cohort of HIV-positive participants attending
HIV outpatient services throughout Australia, of which 20 (74 %) sites report Indigenous status. Data were collected up
until March 2013 and compared between Indigenous and non-Indigenous participants. Person-year methods were
used to compare death rates, rates of loss to follow-up and rates of laboratory testing during follow-up between
Indigenous and non-Indigenous participants. Factors associated with time to first combination antiretroviral therapy
(cART) regimen change were assessed using Kaplan Meier and Cox Proportional hazards methods.
Results: Forty-two of 2197 (1.9 %) participants were Indigenous. Follow-up amongst Indigenous and non-Indigenous
participants was 332 & 16270 person-years, respectively. HIV virological suppression was achieved in similar proportions
of Indigenous and non-Indigenous participants 2 years after initiation of cART (81.0 % vs 76.5 %, p = 0.635). Indigenous
status was not independently associated with shorter time to change from first- to second-line cART (aHR 0.95, 95 % CI
0.51-1.76, p = 0.957). Compared with non-Indigenous participants, Indigenous participants had significantly less
frequent laboratory monitoring of CD4 count (rate:2.76 tests/year vs 2.97 tests/year, p = 0.025) and HIV viral
load (rate:2.53 tests/year vs 2.93 tests/year, p < 0.001), while testing rates for lipids and blood glucose were
almost half that of non-indigenous participants (rate:0.43/year vs 0.71 tests/year, p < 0.001). Loss to follow-up
(23.8 % vs 29.8 %, p = 0.496) and death (2.4 % vs 7.1 %, p = 0.361) occurred in similar proportions of
indigenous and non-Indigenous participants, respectively, although causes of death in both groups were mostly
non-HIV-related.
Conclusions: As far as we are aware, these are the first data comparing clinical outcomes between Indigenous and
non-Indigenous HIV-positive Australians. The forty-two Indigenous participants represent over 10 % of all Indigenous
Australians ever diagnosed with HIV. Although outcomes were not significantly different, Indigenous patients had
lower rates of laboratory testing for HIV and lipid/glucose parameters. Given the elevated risk of cardiovascular disease
in the general Indigenous community, the additional risk factor of HIV infection warrants further focus on modifiable
risk factors to maximise life expectancy in this population.
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Background
The rate of HIV diagnoses among Australian Aboriginal
and Torres Strait Islander (hereafter “Indigenous”)
people over the past decade has been similar to that
among non-Indigenous Australians [1]. However, factors
such as high rates of sexually transmitted infections, so-
cial disadvantage and poor access to health services may
lead to an elevated risk of HIV infection [2], as has been
witnessed among Canada’s Indigenous population [3].
Australia’s Indigenous people are a heterogenous group,
and the diversity of language, socio-cultural, geographic
and economic factors will impact on management of Indi-
genous individuals living with HIV [4]. Compliance with
HIV therapy is recognised as a key factor in disease pro-
gression and prognosis [5], and although challenging in
any setting, it is likely to be complicated by a number of
these factors in Indigenous Australians [6]. Indigenous
people have poorer overall health outcomes and poor ac-
cess to health services [7] which is of specific concern
among those living with HIV as failure to access HIV care
is also an important risk factor for HIV disease progres-
sion [5]. Such issues, along with other co-morbidities in
this population, have the potential to considerably lower
survival rates in Indigenous HIV-infected individuals [6].
There are few published data regarding clinical out-
comes and co-morbidities of Indigenous Australians
living with HIV and it is unknown if these differ from
non-Indigenous HIV-positive Australians. Our aim was
to describe demographic factors, clinical characteristics,
and co-morbidities among Indigenous participants, and
compare them with those of non-Indigenous partici-
pants enrolled in a large Australian clinical cohort of
HIV-positive patients.
Methods
The Australian HIV Observational Database (AHOD)
was established in July 1999. One of the primary objec-
tives of AHOD is to monitor trends in combination anti-
retroviral therapy (cART) use and HIV disease outcomes
among patients with HIV in Australia; areas in which
data from Indigenous individuals are lacking. At the
time of the present analysis, there were 27 AHOD sites
around Australia including HIV tertiary referral centres,
HIV specialist general practice clinics and sexual health
clinics. Consecutive clinic patients were invited to par-
ticipate in AHOD in a non-random manner, thus re-
cruitment of Indigenous patients was coincidental. Key
clinical data are transferred to the co-ordinating centre,
the Kirby Institute, UNSW Australia, on a 6-monthly
basis. These data include patient demographics, HIV dis-
ease stage, and antiretroviral treatment history. Partici-
pant deaths are reported by study sites to The Kirby
Institute AHOD team. The deceased’s attending phys-
ician enters their clinical data into a standardised coding
of causes of death in HIV (CoDe) form [8] and the cause
of death is then determined as being related to HIV or
not. A detailed description of the AHOD cohort has pre-
viously been published [9].
Study population
Analyses were restricted to AHOD sites that report
Indigenous status, recruited to AHOD by March 2013.
Statistical methods
Descriptive statistics were performed comparing key pa-
tient demographic and HIV related clinical information
between Indigenous and non-Indigenous AHOD partici-
pants. Factors investigated include: basic demographic
characteristics; HIV diagnostic characteristics: age at
diagnosis, year of diagnosis, CD4 count at diagnosis &
risk exposure categories; comorbidities: Hepatitis B &
Hepatitis C serology results; antiretroviral treatment fac-
tors: CD4 count at commencement of cART, cART regi-
men prescribed, virological and immunological response
to cART. Loss to follow-up (defined as not having
returned to AHOD clinic in the last 12 months) and
causes of death (AIDS versus non-AIDS related) were
compared between Indigenous and non-Indigenous par-
ticipants. Where relevant, statistical comparisons were
made using chi-square tests for categorical variables, and
independent t-tests or non-parametric equivalent as ap-
propriate, for continuous variables. Person year methods
were used to compare death rates, rates of loss to
follow-up and of laboratory testing during follow-up
between Indigenous and non-Indigenous participants.
Laboratory tests included blood glucose and lipids, as
well as CD4 counts and HIV viral load tests.
Factors associated with time to first cART regimen
change (defined as the addition of two or more drugs to
the regimen, or at least one new cART class being used)
were assessed as a proxy for adherence to, and tolerabil-
ity of, the initial cART regimen prescribed using Kaplan
Meier and Cox Proportional hazards methods as previ-
ously described in detail [10], with a priori inclusion of
Indigenous status in the multivariate model. Off treat-
ment periods were included in duration to time of
change. Risk factors assessed are outlined in Table 2 and
the footnote to Table 2. The model was determined
using backward stepwise methods. Factors in univariate
analyses with p-value < 0.1 were assessed in the multi-
variate analysis. The final model contained factors with
p-value <0.05.
Ethics approval for the AHOD study was granted by
the UNSW Australia Human Research Ethics Commit-
tee, and all other relevant institutional review boards.
Written informed consent was obtained from participat-
ing individuals. All study procedures were developed in
accordance with the revised 1975 Helsinki Declaration.
Templeton et al. BMC Infectious Diseases  (2015) 15:326 Page 2 of 8
Results
The total number of participants recruited to AHOD by
March 2013 was 3894. This analysis included six-monthly
data transfers to end March 2013 for the 20 (74 %) AHOD
sites which reported Indigenous status. Study participants
were 2197 of 2613 (84.1 %) individuals enrolled at these
20 sites for whom Indigenous status was available. There
were 42 (1.9 %) Indigenous participants in our study
population.
Demographic and clinical data at the time of enrol-
ment to AHOD are summarised in Table 1. Characteris-
tics at enrolment were similar for participants with
missing Indigenous status and those for whom Indigen-
ous status was reported (data not shown). However, a
higher proportion (8.9 %) of those with missing Indigen-
ous status reported both male homosexual contact and
injecting drug use (IDU) as potential HIV risk factors,
more participants with missing Indigenous status were
ARV-naïve at enrolment (41.1 %), and more of those
without Indigenous status recorded were missing a CD4
count and HIV viral load measurement at enrolment
(29.1 % & 33.9 %, respectively).
At enrolment, the median age of Indigenous participants
was younger than non-Indigenous participants (37 years,
IQR 32–46 years vs. 41 years, IQR 35–49 years; p = 0.061)
but median time since HIV diagnosis was similar (5.0 years,
IQR 1.7-9.3 years vs 6.5 years, IQR 2.7-11.8 years; p =
0.136). Mean CD4 counts were also similar between Indi-
genous and non-Indigenous participants at enrolment to
AHOD (530/mm3(SD 306/mm3) & 522/mm3(SD 278/
mm3; respectively; p = 0.858). Compared with non-
Indigenous participants, a higher proportion of Indigenous
participants were female (p = 0.029), living in non-
metropolitan areas (p < 0.001), and reported potential HIV
exposures of heterosexual contact (p = 0.022) and injecting
drug use (p = 0.082) (Table 1). In addition, fewer Indigenous
participants reported male-to-male sexual contact alone
as their most likely HIV risk exposure (p = 0.002;
Table 1). Most participants, irrespective of Indigenous
status, had an undetectable HIV viral load, and over
40 % of both groups had a CD4 count of >500/mm3.
Similar proportions of Indigenous and non-Indigenous
participants were currently infected with hepatitis B
(HBsAg positive: 2.4 % vs 3.9 % respectively; p =
0.575) or had evidence of current or past hepatitis C
infection (HCV antibody positive: 16.7 % vs 10.7 %
respectively; p = 0.215). There was little difference at
enrolment between Indigenous and non-Indigenous
participants in total cholesterol (median 4.7 mmol/L
vs. 5.0 mmol/L, respectively, p = 0.679), HDL (median
1.3 mmol/L vs. 1.1 mmol/L, respectively, p = 0.382), tri-
glycerides (median 1.6 mmol/L vs. 1.7 mmol/L, respect-
ively, p = 0.620), and blood glucose (median 4.7 mmol/L
vs 5.1 mmol/L, respectively, p = 0.195) measurements.
Follow-up amongst Indigenous and non-Indigenous par-
ticipants was 332 & 16270 person-years, respectively. Pa-
tient data were available for only 17 (40.5 %) Indigenous
and 882 (40.9 %) non-Indigenous participants at the time of
commencing their first cART regimen. At initiation of ther-
apy, mean CD4 count (360/mm3 vs 430/mm3,p = 0.301)
and proportion starting cART at a CD4 count <200/mm3
(26.7 % vs 17.2 %, p = 0.335) were similar between Indigen-
ous and non-Indigenous participants, respectively. At the
time of cART initiation, few Indigenous (4.2 %) and non-
Indigenous (8.8 %) participants had suffered a prior AIDS-
defining illness (p = 0.715). There was no significant differ-
ence between Indigenous and non-Indigenous participants
in 1st-line cART regimen prescribed (p = 0.879) with most
Indigenous (58.3 %) and non-Indigenous (53.1 %) partici-
pants being prescribed a non-nucleoside reverse transcript-
ase inhibitor (NNRTI)-containing regimen.
HIV viral load measurements were available at 12 and
24 months after cART initiation for 20 (47.6 %) and 21
(50.0 %) Indigenous participants and 950 (44.1 %) and
1005 (44.6 %) non-Indigenous participants. Virological
suppression (defined as HIV viral load <400 copies/ml)
was achieved in similar proportions of Indigenous and
non-Indigenous participants at 12 months post-cART
initiation (60.0 % vs 71.4 %, p = 0.841) and at 24 months
post-cART initiation (81.0 % vs 76.5 %, p = 0.635).
Indigenous status was not independently associated
with shorter time to change from 1st -line to 2nd-line
cART regimen (p = 0.957) when controlling for factors
associated with more rapid change from 1st –line cART
regimen (Table 2).
The rate of laboratory tests during follow-up by Indi-
genous status are outlined in Table 3. Indigenous partici-
pants were tested significantly less often for HIV
markers (CD4 count and HIV viral load), while testing
rates of lipids and blood glucose among Indigenous par-
ticipants were almost half that of non-Indigenous
participants.
The rate of death among Indigenous participants dur-
ing the study period was 0.3/100 person-years (95 % CI
0.07-16.78) compared with 0.93/100 person-years (95 %
CI 0.79-2.00) among non-Indigenous participants (log-
rank p = 0.232). There was only one death among Indi-
genous participants which was attributed to a non-HIV-
related condition, while non-HIV causes of death
accounted for approximately two-thirds (n = 97, 63.8 %)
of deaths in non-Indigenous participants.
Loss to follow-up (LTFU) during the study period
(defined as no clinic visit for ≥ 12 months) was similar
in both groups, occurring among 8 (19.1 %) Indigen-
ous participants (rate 2.41/100 person-years, 95 % CI
1.04-4.75) and 493 (22.9 %) of non-Indigenous partici-
pants (rate 3.03/100 person-years, 95 % CI 2.77-3.31)
(logrank p = 0.531).
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Table 1 Baseline patient characteristics by indigenous status at enrolment to the Australian HIV observational database
Non-indigenous Indigenous Total
(n = 2155) (n = 42) (N = 2197)
n % n % n %
Gender
Female 100 4.6 5 11.9 105 4.8
Male 2051 95.2 36 85.7 2087 95.0
Transgender 4 0.2 1 2.4 5 0.2
Reported HIV exposure
category
Blood products 10 0.5 0 0.00 10 0.5
Heterosexual 170 7.9 8 19.1 178 8.1
IDU 51 2.4 3 7.1 54 2.5
MSM 1812 84.1 28 66.7 1840 83.8
MSM & IDU 60 2.8 1 2.4 61 2.8
Other 24 1.1 1 2.4 25 1.1
missing 28 1.3 1 2.4 29 1.3
Prior AIDS-defining
condition
No 1777 82.5 38 90.5 1815 82.6
Yes 378 17.5 4 9.5 382 17.4
Geographical location of
enrolling clinic
Metropolitan 1777 82.5 21 50.0 1798 81.8
Non-metropolitan 378 17.5 21 50.0 399 19.2
Antiretroviral therapy at
enrolment
Naïve 562 26.1 14 33.3 576 26.2
Prior, not current, therapy 395 18.3 2 4.8 397 18.1
Current mono/dual therapy 76 3.5 1 2.4 77 3.5
3+ II,+/−NRTI,+/−NNRTI,+/−PI 16 0.7 0 0.0 100 4.6
3+ NNRTI + PI,+/−NRTI, No II 96 4.5 1 2.4 485 22.1
3+ NRTI + NNRTI, No PI, No II 545 25.3 13 31.0 562 25.6
3+ NRTI + PI, No NNRTI, No II 426 19.8 7 16.7 433 19.7
3+ NRTI, No PI, No NNRTI, No II 39 1.8 4 9.5 43 2.0
CD4 count at enrolment
(cells per mm3)
<200 199 9.2 3 7.1 202 9.2
200-299 214 9.9 6 14.3 220 10.0
300-499 650 30.2 13 31.0 663 30.2
500+ 989 45.9 18 42.9 1007 45.8
Missing 103 4.8 2 4.8 105 4.8
HIV viral load at enrolment
(copies/ml))
≤400 1245 57.8 25 59.5 1270 57.8
401-10,000 339 15.7 5 11.9 344 15.7
>10,000 470 21.8 10 23.8 480 21.8
Missing 101 4.7 2 4.8 103 4.7
NRTI Nucleoside or nucleotide reverse transcriptase inhibitor, PI Protease inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, II Integrase inhibitor
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Table 2 Multivariate Cox regression analyses for time to change from first- to second- line combination antiretroviral therapy (cART)
n (%) changed Time at risk (PY) Rate of change/100PY AHR 95 % CI p-value Overall p
Indigenous 0.957
No 416 (37.1) 4946.7 14.2 1 - -
Yes 6 (25.0) 112.6 16.0 1.01 0.63-1.63 0.957
Year of HIV diagnosis 0.662
<1997 148 (27.9) 2429.9 15.8 1 - -
≥1997 240 (46.5) 2229.0 12.4 0.96 0.80-1.15 0.662
Missing 34 (35.0) 400.4 15.7 1.15 0.88-1.52 0.300
Year of starting cART <0.001
Prior to 2000 104 (18.5) 2634.5 17.4 1 - -
2000 or later 318 (54.6) 2424.8 10.9 0.54 0.46-0.63 <0.001
Clinic setting <0.001#
General practice 157 (44.5) 1965.9 10.0 1 - -
Hospital outpatient 92 (36.8) 958.1 16.5 1.36 1.10-1.69 0.005
Sexual Health Clinic 173 (32.0) 2135.3 17.2 1.53 1.28-1.83 <0.001
Prior mono or dual
antiretroviral therapy
0.081
No 354 (41.1) 4012.5 12.6 1 1 -
Yes 68 (24.0) 1046.8 20.5 1.24 0.97-1.59 0.081
Hepatitis C antibody positive 0.053
No 389 (37.9) 4600.7 13.9 1 - -
Yes 33 (28.0) 458.6 18.5 1.25 1.00-1.58 0.053
Prior AIDS-defining illness 0.304
No 391 (37.4) 4711.4 13.9 1
Yes 31 (31.3) 348.0 19.5 1.16 0.88-1.52 0.304
CD4 count at time of
commencing cART (per mm3)
0.011*
<200 45 (32.1) 531.0 17.9 1 - -
200-349 82 (43.9) 808.4 13.0 0.85 0.64-1.13 0.267
>350 215 (44.7) 2404.0 11.1 0.73 0.57-0.93 0.010
missing 80 (23.8) 1315.8 19.5 0.96 0.76-1.22 0.746
HIV viral load at time of
commencing cART (copies/ml)
0.200*
≤400 150 (49.3) 1439.0 10.7 1 - -
400-10000 124 (41.1) 1426.6 12.5 1.09 0.87-1.36 0.436
>10000 70 (34.0) 897.2 15.2 1.17 0.92-1.48 0.200
missing 78 (23.5) 1296.5 19.6 1.22 0.60-2.49 0.582
First-line cART regimen <0.001#
PI-containing (no NNRTI or II) 104 (23.8) 1535.4 21.7 1 - -
NNRTI-containing (No PI or II) 290 (47.6) 3185.3 10.0 0.56 0.47-0.65 <0.001
Other (± NNRTI ± PI ± II) 28 (28.6) 338.6 20.7 1.01 0.78-1.32 0.927
Indigenous status included a priori in multivariate model; change defined as addition of ≥ 2 new drugs or ≥ 1 new class in regimen, off treatment periods were
included in duration of time to change; missing categories not included in calculations of p-values. Factors not associated on univariate analysis (p > 0.1) with
shorter time to change from 1st to 2nd line cART were: gender, age at 1st cART, sexual orientation and past/current Hepatitis B infection
PY Person-years, AHR Adjusted hazard ratio, CI Confidence interval, cART combination antiretroviral therapy (at least 3 antiretroviral agents used in combination),
PI protease inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, II Integrase inhibitor
* p for trend, # p for heterogeneity
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Discussion
As far as we are aware, this is the first study comparing a
broad range of HIV clinical outcomes between Indigenous
with non-Indigenous Australians. Adverse clinical out-
comes appeared no more common among Indigenous
participants, although laboratory monitoring of HIV im-
munological and virological markers, as well as fasting
blood glucose and lipids occurred significantly less often
among Indigenous participants.
Although numbers of Indigenous participants were
relatively small, limiting ability for comparison between
groups, the 42 Indigenous participants in fact represent
over 10 % of the total number of Indigenous Australians
who have ever been diagnosed with HIV [1, 11]. As has
been the case with Australian national surveillance of
HIV [4, 12], within AHOD there has been a lack of uni-
form and systematic reporting of Indigenous status.
Thus, some data on Indigenous status was missing and 7
of the 27 AHOD study sites do not report Indigenous
status for any of their participants, potentially limiting
generalisability of our findings. Nonetheless, enrolment
characteristics among AHOD participants were broadly
similar to characteristics of all Indigenous Australians
newly diagnosed with HIV in the last decade, including
HIV being diagnosed at younger age, a higher propor-
tion of infections attributed to injecting drug use and
smaller proportion attributed to MSM contact [1, 13].
Virological suppression is currently considered the
best measure of successful response to cART. Overall in
AHOD more than 80 % of treated participants are viro-
logically suppressed in any calendar year over the last
decade [14], which is broadly similar to the rates of sup-
pression with various cART regimens in other settings
[15–17]. The 2-year virological suppression rates after
commencing cART in our substudy participants of
around 80 % irrespective of Indigenous status is encour-
aging, and is likely to reflect good engagement in care.
The significantly lower rate of testing for immuno-
logical, virological and other health parameters among
Indigenous participants is of concern. The reasons for
less frequent laboratory monitoring of Indigenous partic-
ipants are unclear as such data are not captured in
AHOD. However possible reasons could include eco-
nomic or geographic challenges in accessing care. If such
challenges exist for rural and remote Indigenous people
living with HIV, formal programs providing social, finan-
cial and travel support to enhance HIV monitoring and
care may be beneficial in maintaining their long-term
health. Missed follow-up appointments may be another
possible reason for less frequent monitoring. Missed ap-
pointments for HIV care has been shown to be a strong
predictor of subsequent virologic failure among overseas
clinic populations [18], including among other popula-
tions similarly dispossessed as Australia’s Indigenous
population [19]. The largest disparity by Indigenous sta-
tus was observed for frequency of blood glucose and
lipid measurements which is perhaps of even greater
concern due to the sizeable burden of diabetes and car-
diovascular disease among Indigenous Australians [7].
Clinical outcomes appear no worse among Indigenous
participants enrolled in AHOD compared with their
non-Indigenous counterparts. This may not be represen-
tative of the situation among Indigenous patients outside
the study. It is likely, at least in part, to reflect engage-
ment in HIV care, as enrolment in AHOD requires at-
tendance at a clinical service providing HIV care.
Nonetheless, other health outcomes, such as those
among pregnant HIV-positive Indigenous women, have
been shown to be equivalent to those among non-
Indigenous patients [20], provided that comprehensive,
culturally appropriate, multidisciplinary care is provided.
Reasons for LTFU are not collected in AHOD, and
could possibly include patients transferring care to an-
other (non-AHOD) clinic or to an AHOD clinic which
does not report Indigenous status. We have recently
shown higher viral load, longer time under follow-up and
prior episodes of LTFU are independent predictors of
LFTU in AHOD, although there was no association of
LTFU with death [21]. Of note, loss to follow-up among
participants in this AHOD substudy, irrespective of Indi-
genous status, was slightly lower than that among the en-
tire AHOD cohort over the past 15 years (4.04/100PY, 95
% CI 3.73-4.36) [22]. This suggests better engagement
with HIV care among participants enrolled at sites report-
ing Indigenous status, and again may limit generalisablity
of our findings to the wider Indigenous HIV-positive
population. Adherence is known to be one of the most
important predictors of successful virological suppression
among HIV-positive individuals [23] which we were un-
able to assess in this substudy as very few AHOD sites re-
port adherence to cART. Poor adherence can select for
drug resistance and can shorten the regimen’s durability
[24]. Nonetheless, we examined time to change from 1st
to 2nd line therapy as a proxy for adherence and/or
Table 3 Rate of laboratory tests during follow-up by Indigenous
status
Non-Indigenousa Indigenousb p-value
Variable Rate/year (95 % CI) Rate/year (95 % CI)
Cholesterol 0.71 (0.70-0.72) 0.43 (0.37-0.51) <0.001
HDL 0.53 (0.52-0.55) 0.23 (0.18-0.29) <0.001
Triglycerides 0.71 (0.70-0.72) 0.43 (0.37-0.51) <0.001
Glucose 0.71 (0.70-0.73) 0.43 (0.37-0.51) <0.001
CD4 count 2.97 (2.95-3.00) 2.76 (2.58-2.94) 0.025
HIV viral load 2.93 (2.90-2.96) 2.53 (2.36-2.71) <0.001
anon-Indigenous time at risk: 16270 person-years; bIndigenous time at risk:
332 person-years
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tolerability of the initial cART regimen and this was no
different by Indigenous status. A further limitation was
missing data for a large proportion of participants at time
of commencing their first cART regimen and from the
2 years following cART commencement. These clinical
markers were mostly unavailable as a result of participants
who were recruited to AHOD some years after starting
cART, and often at a different clinical service than that at
which they were first prescribed cART.
Conclusion
Indigenous patients in our large clinical cohort had
lower rates of laboratory testing for HIV and lipid/glu-
cose parameters than non-Indigenous participants.
Overall, lipid and glucose testing among Indigenous par-
ticipants occurred at under half the frequency that is
recommended in national guidelines [25]. Given the ele-
vated risk of cardiovascular disease in the general Indi-
genous community, the additional cardiovascular risk
factor of chronic HIV infection [26] warrants further
focus on modifiable risk factors to maximise life expect-
ancy in this population.
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